-
Acceleron Pharma (XLRN) PT Lowered to $52 at Citi
-
Acceleron Pharma (XLRN) PT Lowered to $61 at Citi
-
Acceleron Pharma (XLRN) PT Raised to $66 at Citi
-
Citi Assumes Acceleron Pharma (XLRN) at Buy
-
Pre-Open Stock Movers 04/05: (BOOT) (TGI) (RIOT) Higher; (SYRS) (AQB) (DLTH) Lower (more...)
-
After-Hours Movers 04/04: (BOOT) (TGI) (FC) Higher; (AQB) (DLTH) (SRYS) (more...)
-
Acceleron Pharma (XLRN) Prices 5.35M Share Common Stock Offering at $43/Share
-
Acceleron Announces Pricing of Public Offering of Common Stock
-
Acceleron Pharma (XLRN) Announces Proposed $200M Share Common Offering
-
Acceleron Announces Proposed Public Offering of Common Stock
-
Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
-
Acceleron to Participate in Three Upcoming Healthcare Investor Conferences
-
Pre-Open Movers 06/29: (GEMP) (DERM) (NKE) Higher; (PFIE) (STZ) (SNX) Lower (more...)
-
Omega's 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More...)
-
Acceleron Pharma (XLRN) PT Raised to $63 at Citi
-
Omega Advisors 13F Shows New Stake in Humana (HUM), Wells Fargo (WFC), Gold ETF (GLD), Sells AET (AET) (More...)
-
Acceleron Announces Closing of Underwriters’ Option to Purchase Additional Shares
-
Acceleron Pharma (XLRN) Prices 5.405M Common Share Offering at $37/Sh
-
Acceleron Announces Pricing of Public Offering of Common Stock
-
Acceleron Pharma (XLRN) Plans $150M Offering of Common Stock
-
Acceleron Announces Proposed Public Offering of Common Stock
-
Citi Upgrades Acceleron Pharma (XLRN) to Buy
-
Acceleron Pharma Reports Third Quarter 2016 Financial and Operational Results
-
Citi Starts Acceleron Pharma (XLRN) at Neutral
-
Acceleron to Participate in Three Healthcare Investor Conferences in September
-
Notable Analyst Rating Changes 8/19: (RH) (ANGI) (SYMC) Upgraded; (BLWD) (NI) (AKS) Downgraded
-
Pre-Open Stock Movers 01/05: (UNIS) (SWHC) (GPRO) Higher; (MNKD) (ABKA) (VRSN) Lower (more...)
-
Acceleron Pharma to Present at Upcoming Investor Conferences in November
-
Acceleron Pharma to Present at Upcoming Investor Conferences in September
-
Three Small Cap Biotech Stocks Added to Citi's Most Preferred List (ATRA) (NVAX) (PBYI)
-
Acceleron Pharma (XLRN) Prices 2.4M Offering at $50/Share
-
Acceleron Pharma (XLRN) Announces $100M Stock Offering
-
Acceleron Pharma (XLRN) Target Lifted to $50 at Citi on Potential Blockbuster Anemia Drugs
-
Citi Starts Acceleron Pharma (XLRN) at Buy
-
Acceleron Pharma (XLRN) IPO Surges on Open
-
Acceleron Pharma (XLRN) IPO Prices at $15, High End of Range
-
Acceleron Pharma (XLRN) Files $74.75M IPO